Viatris And Biocon Launch Bevacizumab Biosimilar In Canada
Abevmy Version Of Avastin Faces Multiple Other Biosimilar Rivals In The Market
Viatris and Biocon have introduced their Abevmy biosimilar bevacizumab version of Avastin in Canada. Marking the third oncology biosimilar – and the fourth biosimilar overall – to be launched by Viatris in Canada, the product will face multiple other approved bevacizumab rivals in the market.
